AEON Biopharma (AEON)

Executive Summary

AEON Biopharma is a clinical-stage biopharmaceutical company focused on developing ABP-450, a proprietary biosimilar to BOTOX® for therapeutic indications. The company aims to expand patient access to botulinum toxin treatments for debilitating conditions such as migraine and cervical dystonia, differentiating itself through a unique injection protocol and exclusive therapeutic focus. While ABP-450 has completed Phase 2 trials in both migraine (NCT04845178) and cervical dystonia (NCT04871451, NCT04849988), a separate migraine trial (NCT05016661) was terminated. Despite these data, the company has not yet advanced to Phase 3, and its path to approval remains uncertain. AEON's strategy could offer significant upside if it can demonstrate non-inferiority to onabotulinumtoxinA, but the terminated trial and competitive landscape present risks. The company's small market cap and early stage suggest high risk but also potential for substantial returns upon successful development or partnership.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 3 Program for ABP-450 in Cervical Dystonia or Migraine35% success
• Q4 2026Regulatory Meeting (e.g., End-of-Phase 2) with FDA50% success
• 2026Strategic Partnership or Licensing Deal for ABP-45030% success